Global Key Players:
The major players in the human microbiome market include Enterome Bioscience (France), Seres Therapeutics (US), 4D Pharma (UK), and Ferring Pharmaceuticals (Switzerland).
Different Growth Strategies Adopted by Them:
Various growth strategies have been adopted by these players, such as agreements, collaborations, partnerships, and acquisitions to increase their presence in the global human microbiome market.
Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904
Overview of This Study:
This market research study involves the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global human microbiome market.
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess market prospects. The human microbiome market's size was estimated through various secondary research approaches and triangulated with inputs from primary research.
Expected Revenue Growth:
The human microbiome market is projected to reach USD 1,598 million by 2028 from USD 894 million in 2025, at a CAGR of 21.3% from 2025 to 2028.
Growth Influencing Factors:
Market growth is largely driven by the increasing focus on the development of human microbiome therapy. It has also become a validated target for drug development. The growing number of collaborations between market players is also expected to offer a wide range of growth opportunities for market players during the forecast period. However, a lack of expertise and inadequate research on the human microbiome are factors expected to restrain this market's growth.
Enterome Bioscience (France) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat microbiome-associated diseases with a focus on IBDs, Crohn’s, and cancer (glioblastoma, colon, pancreatic, lung, and breast) indications. To sustain its position in the human microbiome market, ENTEROME adopts various organic and inorganic growth strategies.
The company has been consistently entering into agreements and partnerships with strong biopharmaceutical players, which will help it to expedite drug development for cancer and GI disorders. In 2020, the company received funds of USD 52.6 million from investors, including SymBiosis, LLC (US), a microbiome-focused investment vehicle, and Takeda Pharmaceutical Company Limited (Japan) for the progress of clinical development of its therapeutic pipeline. This pipeline includes the first clinical trials of EO2401, a novel OncoMimic cancer immunotherapy.
Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=37621904
Seres Therapeutics (US) is one of the emerging players operating in this market. The company is engaged in developing a range of novel therapeutic products based on the human microbiome. To sustain its position in the human microbiome market, Seres Therapeutics focuses on its products offered for the market.
The company’s microbiome therapeutics platform allows to significantly reduces the time typically required to advance therapeutics to the clinic, and ultimately, to the market. The company’s SER-109 program for the treatment of recurrent C difficile infection is anticipated to be the first-ever FDA-approved microbiome therapy. This has helped the company to strengthen its market position in high-growth niche opportunities.
